Services

R&D Plant-Based Medicines

At IMP, we cover all stages of development for cannabinoid-based medicines.

Biodiversity and plant selection: R&D in this field involves identifying and selecting plants with promising medicinal properties. This requires in-depth knowledge of cannabis biotechnology and the study of its chemotypes.

At IMP, we are committed to the development of investigational medicines for clinical phases.

Manufacturing / Derivatives / Cannabinoids

Isolation and Characterization of Active Compounds: Once the plants are selected, the active compounds present in them are isolated and characterized. This process involves advanced techniques in the separation and isolation of organic compounds, aiming to identify and purify the active ingredients with therapeutic potential, and to scale them up for the manufacturing of investigational medicines.

IMP specializes in the production of DRONABINOL, active pharmaceutical ingredients and tailor-made manufacturing intermediates.

Pharmaceutical Consulting

We support our clients—as future players in the pharmaceutical sector—in integrating into the value chain by providing technical and regulatory support at every stage of GMP implementation and pharmaceutical plant setup:

• Selection of facilities and equipment.
• Staff training and assistance in recruiting pharmaceutical profiles.
• Technology transfer and Know-How in the development of cannabis strains with therapeutic interest.
• Process validations and qualification of equipment and facilities.
• Regulatory framework: Opening of a new pharmaceutical plant.

Cannabis Product Distribution

IMP also distributes the following products with GACP/GMP pharmaceutical certification.

• THC Chemotype Cannabis Flower as a final drug product.
• THC Chemotype Distilled Extract as an active ingredient for drug manufacturing.
• Dronabinol (THC >95%).